2022-RA-1297-ESGO A subgroup analysis of response rate by patient characteristics in patients with endometrial cancer receiving monotherapy dostarlimab in the GARNET trial

Ana Oaknin; Bhavana Pothuri; Lucy Gilbert; Renaud Sabatier; Jubilee Brown; Sharad Ghamande; Cara Mathews; David M O’Malley; Rebecca Kristeleit; Valentina Boni; Adriano Gravina; Susana Banerjee; Rowan E Miller; Joanna Pikiel; Mansoor R Miza; Tao Duan; Yuping Dong; Eleftherios Zografos; Jennifer Veneris; Anna V Tinker; NEXT Oncology Hospital Universitario Quirónsalud *Affiliation at time of study. Current affiliation

doi:10.1136/ijgc-2022-ESGO.302

Article info

Endometrial cancer

2022-RA-1297-ESGO A subgroup analysis of response rate by patient characteristics in patients with endometrial cancer receiving monotherapy dostarlimab in the GARNET trial

Free

Authors

Ana Oaknin Gynaecologic Cancer Programme, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain PubMed articles Google scholar articles
Bhavana Pothuri Department of Obstetrics/Gynecology, Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY PubMed articles Google scholar articles
Lucy Gilbert Division of Gynecologic Oncology, McGill University Health Centre, Montreal, QC, Canada PubMed articles Google scholar articles
Renaud Sabatier Department of Medical Oncology, Institut Paoli Calmettes, Aix-Marseille University, Marseille, France PubMed articles Google scholar articles
Jubilee Brown Division of Gynecologic Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC PubMed articles Google scholar articles
Sharad Ghamande Department of Obstetrics & Gynecology, Georgia Cancer Center, Augusta University, Augusta, GA PubMed articles Google scholar articles
Cara Mathews Women and Infants Hospital of Rhode Island, Providence, RI PubMed articles Google scholar articles
David M O’Malley Division of Gynecologic Oncology Oncology and Gynecologic Oncology Phase I Program, The Ohio State University and the James Cancer Center, Columbus, OH PubMed articles Google scholar articles
Rebecca Kristeleit Guy’s and St. Thomas’ Hospital NHS Foundation Trust, London, United Kingdom PubMed articles Google scholar articles
Valentina Boni START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid, Spain PubMed articles Google scholar articles
Adriano Gravina Clinical Trial Unit, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy PubMed articles Google scholar articles
Susana Banerjee Gynaecology Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom PubMed articles Google scholar articles
Rowan E Miller University College London, St. Bartholomew’s Hospitals London, London, United Kingdom PubMed articles Google scholar articles
Joanna Pikiel Department of Chemotherapy, Regional Center of Oncology, Gdansk, Poland PubMed articles Google scholar articles
Mansoor R Miza Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark and Nordic Society of Gynaecologic Oncology-Clinical Trial Unit, Copenhagen, Denmark PubMed articles Google scholar articles
Tao Duan GSK, Pennington, NJ PubMed articles Google scholar articles
Yuping Dong GSK, Pennington, NJ PubMed articles Google scholar articles
Eleftherios Zografos GSK, London, United Kingdom PubMed articles Google scholar articles
Jennifer Veneris GSK, Waltham, MA PubMed articles Google scholar articles
Anna V Tinker Department of Medicine, British Columbia Cancer, Vancouver Centre, University of British Columbia, Vancouver, BC, Canada PubMed articles Google scholar articles
NEXT Oncology Hospital Universitario Quirónsalud *Affiliation at time of study. Current affiliation
Google scholar articles

Citation

Oaknin A, Pothuri B, Gilbert L, et al

2022-RA-1297-ESGO A subgroup analysis of response rate by patient characteristics in patients with endometrial cancer receiving monotherapy dostarlimab in the GARNET trial

International Journal of Gynecologic Cancer 2022;32:A141-A142.

Publication history

First published October 20, 2022.

Online issue publication

October 27, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password